Longeveron Inc. 2021 Form 10-K Summary
Business Context and Reporting Period
Longeveron is a clinical-stage biotechnology company developing Lomecel-B, an allogeneic bone-marrow-derived medicinal signaling cell therapy for aging-related and life-threatening conditions. Programs included Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, acute respiratory distress syndrome and hypoplastic left heart syndrome.
The filing covers the fiscal year ended December 31, 2021, with comparative results for 2020. Although the request identifies 2021 Q4, the source is an annual Form 10-K rather than a quarterly filing. The company completed its conversion from an LLC to a Delaware corporation and completed its Nasdaq IPO in February 2021.
Financial Performance and Liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $1.306 million | $5.629 million | Down 77% |
| Gross profit | $0.590 million | $1.826 million | Down 68% |
| Gross margin | Approximately 45% | Approximately 32% | Improved |
| Operating expenses | $18.046 million | $5.604 million | Up 222% |
| Loss from operations | $17.456 million | $3.778 million | Significantly higher loss |
| Net loss | $17.045 million | $3.721 million | Up 358% |
| Net loss per share | $0.90 | $0.23 | Higher loss per share |
| Cash flow from operations | $(9.636) million | $(2.364) million | Greater use of cash |
| Cash flow from investing | $(10.696) million | $(0.261) million | Greater use of cash |
| Cash flow from financing | $45.174 million | $1.575 million | Higher inflows |
Revenue consisted of $0.598 million of grant revenue and $0.708 million of clinical trial revenue. Grant revenue declined 86% as several grant-funded trials were completed. Clinical trial revenue declined 46%, primarily because COVID-19-related travel restrictions reduced participation in the Bahamas Registry Trial. Contract revenue was zero in 2021 versus $0.055 million in 2020.
General and administrative expense increased to $10.734 million, including approximately $4.2 million of equity-based compensation, higher insurance costs and investor-relations costs. Research and development expense increased to $7.092 million, including approximately $2.2 million of equity-based compensation and higher clinical trial costs.
At December 31, 2021, the company held $25.658 million of cash and cash equivalents and $9.385 million of short-term investments, for approximately $35.0 million of liquid resources. Working capital was approximately $32.7 million. Total liabilities were $5.313 million, including $3.142 million of operating lease liabilities; the company reported no outstanding loans at year-end. Accumulated deficit was $43.938 million.
Financing included net IPO proceeds of approximately $26.7 million, net proceeds of approximately $18.5 million from the December 2021 private placement, and approximately $0.6 million from warrant exercises. The private placement included warrants for 1,169,288 shares with an initial exercise price of $17.50 per share, plus representative warrants.
Material Changes and Operating Developments
- The company’s Phase 2b Aging Frailty trial enrolled 148 subjects and completed in the first quarter of 2021. The primary six-minute walk test endpoint at Month 6 was not statistically significantly different from placebo, although certain Month 9 exploratory comparisons and pooled analyses were statistically significant.
- The Phase 2b trial did not show statistically significant differences versus placebo for key secondary measures including PROMIS physical function and TNF-alpha. Management continued evaluating subgroup and biomarker data before determining the next regulatory and development steps.
- A 48-patient Phase 2a Alzheimer’s disease trial began screening in the fourth quarter of 2021.
- The Phase 1 ARDS trial and the 38-subject ELPIS II Phase 2 HLHS trial were ongoing and enrolling. As of February 2022, six patients had been enrolled in the COVID-19 ARDS trial and four additional patients had received treatment under expanded access.
- Japan’s PMDA approved a clinical trial notification for a Phase 2 Aging Frailty study, expected to begin in the first half of 2022.
- The FDA granted Rare Pediatric Disease and Orphan Drug designations for Lomecel-B for HLHS in 2021. These designations do not assure approval, a priority review voucher or orphan exclusivity.
- Equity-based compensation expense increased to approximately $6.4 million from $0.039 million in 2020. Approximately $3.1 million of unrecognized equity compensation remained at year-end, expected to be recognized over approximately three years.
Guidance, Outlook, Risks and Unusual Items
Management stated that cash and cash equivalents and investments at December 31, 2021 were expected to fund operating expenses and capital expenditures through at least 2022 or, in the audited financial statement liquidity disclosure, at least the next 12 months from issuance. The company also stated that additional capital will be needed as clinical development, manufacturing, regulatory and public-company expenses increase. No revenue or profitability guidance was provided.
- Longeveron has no approved products, no material product-sales revenue and has incurred recurring operating losses since inception. Management expects additional losses for the foreseeable future.
- Clinical success and regulatory approval remain uncertain. Aging Frailty and Metabolic Syndrome lack consensus regulatory definitions and acceptable endpoints, potentially complicating or delaying pivotal trials.
- COVID-19 disrupted clinical follow-up, international travel and the Bahamas Registry Trial, and could continue to affect enrollment, trial timelines, manufacturing and financing access.
- The company depends on third-party bone-marrow suppliers, specialized materials, clinical research organizations and research institutions. Supply interruptions or manufacturing-scale-up difficulties could delay development.
- A securities class-action lawsuit filed in September 2021 alleges materially false or misleading statements in IPO materials and subsequent disclosures. The company believes the claims are without merit; the potential loss could not be estimated.
- The company had $3.1 million of operating lease obligations and $4.3 million of contract research organization obligations at year-end. Additional milestone and royalty payments may arise, including potential payments to the University of Miami and revenue-sharing obligations under an Alzheimer’s Association grant.
- Cash resources include investments exposed to interest-rate and credit-market changes, although management stated that a 100-basis-point immediate rate change would not materially affect fair value.
- Class B holders controlled approximately 93% of combined voting power at December 31, 2021, creating significant control and governance risk for Class A shareholders.
Most Important Facts for Investors to Verify
- Whether follow-up analyses from the Aging Frailty Phase 2b trial support an FDA-agreed pivotal development path despite failure of the primary Month 6 endpoint.
- The enrollment pace, safety findings and efficacy signals from the Alzheimer’s, HLHS, ARDS and Japan Aging Frailty studies.
- The company’s actual cash burn and financing runway relative to management’s stated funding outlook.
- Future equity financing needs, warrant exercises, potential dilution and the effect of the private-placement warrant repricing provisions.
- The status and potential exposure of the securities lawsuit and other contractual, royalty or milestone obligations.
- Whether manufacturing capacity, bone-marrow supply and regulatory compliance can support larger clinical trials and eventual commercialization.
- The effect of COVID-19, trial delays, patient attrition and changing regulatory requirements on clinical timelines.